<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Investor Brief – Pediatric Pulmonary Valve Market</title>
  <style>
    :root{
      --bg:#0b1220;--panel:#121a2b;--muted:#30415f;--card:#0f1626;--text:#ebf2ff;--accent:#4cc9f0;--accent-2:#a3ffb0;--warn:#ffd166;
      --shadow:0 10px 30px rgba(0,0,0,.25);
      --radius:16px;
    }
    *{box-sizing:border-box}
    html,body{height:100%}
    body{margin:0;background:linear-gradient(180deg,var(--bg),#0a0f1a);color:var(--text);font-family:Inter,ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial;line-height:1.45}
    a{color:var(--accent);text-decoration:none}
    a:hover{text-decoration:underline}
    .app{display:grid;grid-template-columns:280px 1fr;min-height:100vh}
    aside{background:var(--panel);padding:20px;border-right:1px solid #1f2b44}
    main{padding:28px 32px}
    .brand{display:flex;align-items:center;gap:12px;margin-bottom:16px}
    .logo{width:36px;height:36px;border-radius:10px;background:linear-gradient(135deg,var(--accent),#5ef0c4)}
    h1{font-size:22px;margin:0}
    .subtle{color:#b7c3d7;font-size:12px}
    nav ul{list-style:none;padding:0;margin:10px 0 0}
    nav li{margin:4px 0}
    .nav-link{display:flex;align-items:center;gap:10px;padding:10px 12px;border-radius:10px;color:#cfe3ff}
    .nav-link:hover{background:#0a1324}
    .chip{font-size:11px;padding:2px 8px;border:1px solid var(--muted);border-radius:999px;color:#a6b6d6}
    .section{scroll-margin-top:90px;margin-bottom:28px}
    .header{position:sticky;top:0;background:linear-gradient(180deg,rgba(11,18,32,.98),rgba(11,18,32,.85));backdrop-filter:blur(8px);z-index:20;padding:14px 24px;border-bottom:1px solid #17233a;display:flex;align-items:center;gap:14px}
    .header h2{margin:0;font-size:18px}
    .grid{display:grid;gap:16px}
    .grid.cols-2{grid-template-columns:repeat(2,minmax(0,1fr))}
    .grid.cols-3{grid-template-columns:repeat(3,minmax(0,1fr))}
    @media (max-width:1100px){.app{grid-template-columns:1fr}.grid.cols-2{grid-template-columns:1fr}.grid.cols-3{grid-template-columns:1fr 1fr}}
    @media (max-width:720px){.grid.cols-3{grid-template-columns:1fr}}
    .card{background:linear-gradient(180deg,var(--card),#0a0f1a);border:1px solid #1b2742;border-radius:var(--radius);padding:18px;box-shadow:var(--shadow)}
    .card h3{margin:0 0 6px;font-size:16px}
    .muted{color:#9fb0cc}
    .pill{padding:4px 8px;border-radius:8px;background:#0e1b32;border:1px solid #22365b;color:#a6bee6}
    .btn{display:inline-flex;align-items:center;gap:10px;background:linear-gradient(180deg,#182844,#0e1a30);border:1px solid #213358;border-radius:12px;padding:10px 12px;color:#cfe3ff}
    .btn:hover{filter:brightness(1.1)}
    .sep{height:1px;background:#1a2743;margin:14px 0}
    .table{width:100%;border-collapse:separate;border-spacing:0 8px}
    .table th{font-weight:600;font-size:12px;text-transform:uppercase;letter-spacing:.04em;color:#9fb0cc;text-align:left;padding:0 12px}
    .table td{background:#0b1426;border:1px solid #1b2742;border-left:none;border-right:none;padding:12px;border-radius:10px}
    .table tr td:first-child{border-left:1px solid #1b2742;border-top-left-radius:12px;border-bottom-left-radius:12px}
    .table tr td:last-child{border-right:1px solid #1b2742;border-top-right-radius:12px;border-bottom-right-radius:12px}
  </style>
</head>
<body>
<div class="app">
  <aside>
    <div class="brand">
      <div class="logo" aria-hidden="true"></div>
      <div>
        <h1>Investor Brief</h1>
        <div class="subtle">Confidential – For Broadview Ventures</div>
      </div>
    </div>
    <nav>
      <ul>
        <li><a class="nav-link" href="./index.html">← Back to Index</a></li>
        <li><a class="nav-link" href="./Consolidated_Deep_Dive_Dashboard_client_friendly.html">← Back to Consolidated Dashboard</a></li>
        <li class="sep"></li>
        <li><span class="chip">Sections</span></li>
        <li><a class="nav-link" href="#summary">Executive Summary</a></li>
        <li><a class="nav-link" href="#thesis">Investment Thesis</a></li>
        <li><a class="nav-link" href="#valuation">Valuation Anchors</a></li>
        <li><a class="nav-link" href="#use">Use of Proceeds</a></li>
        <li><a class="nav-link" href="#competition">Competitive Landscape</a></li>
        <li><a class="nav-link" href="#comps">Recent M&A Comps</a></li>
        <li><a class="nav-link" href="#risks">Risks & Mitigants</a></li>
        <li><a class="nav-link" href="#appendix">Appendix (Cap Table & IRR)</a></li>
        <li><a class="nav-link" href="#funds">Fund Benchmark Context</a></li>
      </ul>
    </nav>
  </aside>
  <main>
    <header class="header">
      <h2>Investor Brief – Pediatric Pulmonary Valve</h2>
      <span class="pill">Series A Opportunity • Exit $250M Midpoint</span>
      <a href="./Consolidated_Deep_Dive_Dashboard_client_friendly.html" class="btn" style="margin-left:auto">Back to Dashboard</a>
    </header>

    <section id="summary" class="section">
      <div class="card">
        <h3>Executive Summary</h3>
        <p>The pediatric pulmonary valve market is a niche but high-impact opportunity: U.S. TAM of $125–140M in 2025 trending toward $180–200M by 2030, with global expansion from $300M in 2024 to $677M in 2035. Autus Valve’s growth-accommodating design addresses a $2.2M lifetime patient cost burden and is positioned for trade sale at $150–400M, midpoint $250M.</p>
      </div>
    </section>

    <section id="thesis" class="section">
      <div class="card">
        <h3>Investment Thesis</h3>
        <ul>
          <li>Current prosthetic valves cannot grow; average patient incurs 2–3 re-ops before adulthood and $2.2M lifetime cost burden.</li>
          <li>Autus Valve: one-time surgical implant + serial cath expansions; FDA Breakthrough designation; pivotal study active.</li>
          <li>Premium ASP justified by avoided surgeries and payer HEOR dossier.</li>
        </ul>
      </div>
    </section>

    <section id="valuation" class="section">
      <div class="grid cols-2">
        <div class="card">
          <h3>Valuation Anchors</h3>
          <ul>
            <li>Series A: $30M pre / $45M post, $15M raise.</li>
            <li>Ownership: 33.3%, with 15% ESOP.</li>
            <li>Exit target: $250M midpoint (range $150–400M).</li>
          </ul>
        </div>
        <div class="card">
          <h3>Multiples by Stage</h3>
          <table class="table">
            <thead><tr><th>Stage</th><th>Valuation Range</th><th>Median</th></tr></thead>
            <tbody>
              <tr><td>Pre‑rev (Breakthrough)</td><td>$12–80M</td><td>~$20M</td></tr>
              <tr><td>Clinical (positive data)</td><td>$5–75M</td><td>~$14M</td></tr>
              <tr><td>Commercial specialty</td><td>$3–63M</td><td>~$16M</td></tr>
            </tbody>
          </table>
        </div>
      </div>
    </section>

    <section id="use" class="section">
      <div class="grid cols-2">
        <div class="card">
          <h3>Use of Proceeds (18–24 months)</h3>
          <ul>
            <li>Clinical: pivotal study execution (sites, monitoring, core lab).</li>
            <li>Regulatory: IDE maintenance, PMA planning, interactions.</li>
            <li>Manufacturing: process validation, sterilization, supply chain scale-up.</li>
            <li>HEOR/Market: dossier, KOL engagement, reference centers.</li>
            <li>BD: strategic partnership discussions ahead of PMA.</li>
          </ul>
        </div>
        <div class="card">
          <h3>Competitive Positioning</h3>
          <p>Autus is uniquely positioned vs. Medtronic (fixed-size Melody/Harmony) and emerging players (Renata, PECA, PolyVascular, Xeltis). Only Autus directly addresses growth accommodation with synthetic durability.</p>
        </div>
      </div>
    </section>

    <section id="competition" class="section">
      <div class="card">
        <h3>Competitive Landscape</h3>
        <ul>
          <li><b>Autus Valve</b>: growth-accommodating synthetic valve; pivotal trial active.</li>
          <li><b>Medtronic Melody/Harmony</b>: FDA-approved TPVs; fixed-size tissue valves.</li>
          <li><b>Renata Medical</b>: Minima stent; FDA-approved growth-accommodating stent.</li>
          <li><b>Xeltis</b>: restorative bioabsorbable conduit; EU pivotal.</li>
          <li><b>PECA Labs</b>: MASA surgical conduit; early feasibility IDE.</li>
          <li><b>PolyVascular</b>: polymeric TPV for young children; early clinical.</li>
          <li><b>Annoviant</b>: TxGuard regenerative conduit; NIH-backed, early clinical.</li>
        </ul>
      </div>
    </section>

    <section id="comps" class="section">
      <div class="card">
        <h3>Recent M&A Comps</h3>
        <table class="table">
          <thead><tr><th>Acquirer</th><th>Target</th><th>Year</th><th>Value</th></tr></thead>
          <tbody>
            <tr><td>Edwards Lifesciences</td><td>CardiAQ Valve Technologies</td><td>2015</td><td>$320M</td></tr>
            <tr><td>Boston Scientific</td><td>Apama Medical</td><td>2017</td><td>$300M</td></tr>
            <tr><td>Abbott</td><td>Cardiovascular Systems Inc.</td><td>2023</td><td>$851M</td></tr>
            <tr><td>Johnson & Johnson</td><td>V-Wave</td><td>2024</td><td>$600M upfront (+ milestones)</td></tr>
          </tbody>
        </table>
      </div>
    </section>

    <section id="risks" class="section">
      <div class="grid cols-2">
        <div class="card">
          <h3>Risks</h3>
          <ul>
            <li>Durability risk: multi-expansion fatigue/calcification must be validated.</li>
            <li>Regulatory: PMA timeline is long; pivotal follow-up up to 10 years.</li>
            <li>Niche pediatrics: small patient pool.</li>
          </ul>
        </div>
        <div class="card">
          <h3>Mitigants</h3>
          <ul>
            <li>Bench/animal + pivotal trial designed to stress-test expansions.</li>
            <li>Breakthrough Device designation expedites FDA engagement.</li>
            <li>Premium pricing; crossover to adult congenital and global markets.</li>
          </ul>
        </div>
      </div>
    </section>

    <section id="appendix" class="section">
      <div class="grid cols-2">
        <div class="card">
          <h3>Cap Table Snapshot (Series A)</h3>
          <table class="table">
            <thead><tr><th>Holder</th><th>Pre-A %</th><th>Post-A %</th></tr></thead>
            <tbody>
              <tr><td>Founders & Early Holders</td><td>77.5%</td><td>51.7%</td></tr>
              <tr><td>ESOP</td><td>22.5%</td><td>15.0%</td></tr>
              <tr><td>Series A Investors</td><td>—</td><td>33.3%</td></tr>
            </tbody>
          </table>
        </div>
        <div class="card">
          <h3>Exit IRR Math</h3>
          <ul>
            <li>Exit: $250M midpoint.</li>
            <li>Ownership: 33.3% at close → 30% at exit (10% dilution).</li>
            <li>5× MOIC → ~31% IRR over 6 years.</li>
          </ul>
        </div>
      </div>
    </section>

    <section id="funds" class="section">
      <div class="card">
        <h3>Fund Benchmark Context (Q4 2024)</h3>
        <p>Global medtech and healthcare-focused venture funds delivered median net TVPI of ~1.4× and IRRs in the 12–15% range in Q4 2024, per industry reports. Top-quartile healthcare/medtech funds posted 2.0–2.5× net TVPI with IRRs above 20%. These benchmarks contextualize Autus Valve’s Series A opportunity, where a 5× MOIC and 30%+ IRR on a $250M exit midpoint materially outperforms recent sector norms, aligning with Broadview’s mandate to back high-impact, high-return pediatric innovations.</p>
      </div>
    </section>

    <section class="section">
      <div class="muted">© 2025 Osprey Intel LLC • Prepared for Broadview Ventures. Investor Brief synthesizes financial and market data from Osprey Intel research and analysis, IC memo, valuation models, cap table simulations, and global fund benchmarks.</div>
    </section>

  </main>
</div>
</body>
</html>
